Defence's Successful Results on Its AccuTOX Anti-Cancer ARM Vaccine Creates a Potent Second-Generation Anti-Cancer ARM-002 Vaccine

Published on March 27, 2024

3/26/2024

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biotechnology company developing novel

 


(Feed generated with FetchRSS)

 

Continue reading on website
Other news

ME Therapeutics Holdings Inc. Announces Upcoming Participation in the 2024 Bloom Burton & Co Health Care Conference and Interview On CSE TV

March 27, 2024
Vancouver, British Columbia--(Newsfile Corp. - March 26, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce that the Company's CEO, Dr. Salim Dhanji, will attend and participate in one-on-one meetings at the 2024 Bloom Burton & Co. Healthcare Investor

Finding the future of AI with exhibitors at MaRS Impact AI

March 28, 2024
Check out what the exhibitors at #MaRSImpactAI say about the future of AI, and whether technology can be our friend.The post Finding the future of AI with exhibitors at MaRS Impact AI appeared first on MaRS Discovery District.